98%
921
2 minutes
20
Robot-assisted simple prostatectomy (RASP) has demonstrated better peri-operative outcomes as compared to open simple prostatectomy. However, RASP is still limited by platform availability and cost-effectiveness issues. The new surgical robots increasing competition may spread the robotic approach also in non-oncological fields. We reported the first RASP executed in Europe at OLV Hospital (Aalst, Belgium) performed with the novel HUGO™ Robot-Assisted Surgery (RAS) System. The platform consists of four independent carts, an open console, and a system tower equipped for both laparoscopic and robotic surgery. Our main goal was to demonstrate the technical feasibility of RASP with the novel HUGO™ RAS along with its safety in terms of perioperative outcomes and complications. We also aimed to describe our surgical setup. We collected patient's baseline characteristics, intraoperative and perioperative complications, postoperative outcomes, docking time, operative time, clashing of the instruments, or technical errors of the system. The procedure was performed in a 72-year-old male with a prostate volume of 155 g at preoperative imaging. No need for conversion to open/laparoscopic surgery and/or for additional port placement was required. No intraoperative complications, instrument clashes, or failure of the system that compromised the completion of the surgery were recorded. Docking, operative, and console times were 9, 150, and 120 minutes, respectively. The catheter was removed on the second postoperative day. No postoperative complications occurred. The postoperative uroflowmetry revealed a maximum flow of 26.2 mL/s, without postvoid residual volume. Robot-assisted simple prostatectomy with the HUGO™ RAS System is a feasible and safe procedure in terms of perioperative outcomes and complications. Our setup allowed for a rapid docking procedure and a smoothly completion of the surgery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.23736/S2724-6051.22.05031-5 | DOI Listing |
Can J Urol
August 2025
Department of Urology, Duke University Hospital, Durham, NC 27710, USA.
Background: Radical prostatectomy has long been the treatment of choice for men with clinically significant prostate cancer (PCa) in those with concurrent significant lower urinary tract symptoms (LUTS). For men who meet this description with marked prostatomegaly, we present a multi-institutional proof of concept study describing an alternative pathway of robotic simple prostatectomy (RASP) followed by external beam radiation therapy (EBRT) for the treatment of clinically significant prostate cancer.
Methods: A retrospective study was performed of 17 patients with PCa who underwent RASP followed by EBRT at two institutions from 2015-2023.
Aims: The aim of this study was to develop and verify a new emergence agitation risk prediction model based on the electronic medical records of patients undergoing transurethral resection of the prostate.
Background: The incidence of prostate disease in elderly men is high, and the harm caused by emergence agitation in patients after transurethral resection of the prostate is serious. It is necessary to develop a predictive model for emergence agitation in patients undergoing transurethral resection of the prostate.
Urol Res Pract
July 2025
Department of Urology, Shahid Beheshti University of Medical Sciences, Shahid Modarress Hospital, Tehran, Iran.
Objective: This retrospective cross-sectional study aimed to compare functional and surgical outcomes after open simple prostatectomy (OSP) between patients who underwent prior transurethral resection of the prostate (TURP) and those who did not. Methods: Between March 2009 and April 2019, 723 patients underwent TURP, of whom 20 (2.7%) subsequently underwent OSP (Group 1).
View Article and Find Full Text PDFJ Robot Surg
August 2025
Department of Urology, Affiliated Hospital of North Sichuan Medical College, No. 1 Mao Yuan South Road, Wenhua Road 57, Shunqing, Nanchong, 637000, Sichuan, People's Republic of China.
With the rising prevalence of benign prostatic hyperplasia (BPH), there is an increasing demand for surgical interventions that optimize patient outcomes while minimizing complications. This systematic review aims to critically evaluate and contrast the clinical outcomes, surgical efficiency, and safety profiles during the perioperative period for holmium laser enucleation of the prostate (HoLEP) and robot-assisted simple prostatectomy (RASP) in patients diagnosed with BPH exhibiting a prostate volume of ≥ 80 mL, providing evidence-based insights for BPH management. Adhering to the EAU Guidelines Office and PRISMA guidelines, the study protocol was registered with Prospero [CRD420251059418].
View Article and Find Full Text PDFJ Endourol
August 2025
The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Short-term outcomes of Aquablation as the treatment for benign prostatic hyperplasia (BPH) have not been well characterized. The aim of this analysis was to compare rates of 30- and 90-day complications following Aquablation with those after transurethral resection of prostate (TURP), UroLift, holmium laser enucleation of the prostate (HoLEP), and laparoscopic simple prostatectomy (SP). Using the TriNetX Research database, a collaborative claims and electronic medical record research network of 79 large health care organizations, we conducted a propensity-matched retrospective cohort study of all patients who underwent Aquablation (Current Procedural Terminology [CPT] 0421T or Healthcare Common Procedure Coding System ((HCPCS) C2596), TURP (CPT 52601), UroLift (CPT 52441), HoLEP (CPT 52649), or laparoscopic SP (CPT 55866, 55867) between the dates of January 1, 2017, and December 31, 2023.
View Article and Find Full Text PDF